Status: Recruiting
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Participants needed: 150
Trial details
Age: 12+Biological sex: AllType: ObservationalSponsor: Alnylam PharmaceuticalsUpdated: Apr 27, 2026Locations: 30
Eligibility criteria
Documented diagnosis of AHP, per physician's determination
Currently enrolled in a clinical trial for any investigational agent